- Home
- CET vs SDGR Comparison
CET vs SDGR Comparison
Compare CET & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CET
- SDGR
- Stock Information
- Founded
- CET 1929
- SDGR 1990
- Country
- CET United States
- SDGR United States
- Employees
- CET N/A
- SDGR N/A
- Industry
- CET Finance/Investors Services
- SDGR Biotechnology: Pharmaceutical Preparations
- Sector
- CET Finance
- SDGR Health Care
- Exchange
- CET Nasdaq
- SDGR Nasdaq
- Market Cap
- CET 1.4B
- SDGR 1.4B
- IPO Year
- CET N/A
- SDGR 2020
- Fundamental
- Price
- CET $50.22
- SDGR $19.13
- Analyst Decision
- CET
- SDGR Buy
- Analyst Count
- CET 0
- SDGR 7
- Target Price
- CET N/A
- SDGR $28.43
- AVG Volume (30 Days)
- CET 21.5K
- SDGR 1.2M
- Earning Date
- CET 01-01-0001
- SDGR 08-06-2025
- Dividend Yield
- CET 4.45%
- SDGR N/A
- EPS Growth
- CET N/A
- SDGR N/A
- EPS
- CET 7.40
- SDGR N/A
- Revenue
- CET $27,062,484.00
- SDGR $237,917,000.00
- Revenue This Year
- CET N/A
- SDGR $23.71
- Revenue Next Year
- CET N/A
- SDGR $21.80
- P/E Ratio
- CET $6.83
- SDGR N/A
- Revenue Growth
- CET 15.78
- SDGR 18.59
- 52 Week Low
- CET $40.24
- SDGR $16.60
- 52 Week High
- CET $50.97
- SDGR $28.47
- Technical
- Relative Strength Index (RSI)
- CET 63.82
- SDGR 42.78
- Support Level
- CET $49.50
- SDGR $18.69
- Resistance Level
- CET $50.55
- SDGR $20.08
- Average True Range (ATR)
- CET 0.67
- SDGR 0.72
- MACD
- CET 0.00
- SDGR 0.01
- Stochastic Oscillator
- CET 64.11
- SDGR 25.07
About CET Central Securities Corporation
Central Securities Corp is a non-diversified closed-end management investment company. Its investment objective is long-term growth of capital. The company invests in common stocks, bonds, convertible bonds, preferred stocks, convertible preferred stocks, warrants, options real estate, or short-term obligations of governments, banks, and corporations.
About SDGR Schrodinger Inc.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.